Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer (Q36950482)

17 August 2017

1 reference

title

Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer (English)

1 reference

17 August 2017

Susanne Briest

1

1 reference

17 August 2017

Antonio C Wolff

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1243-1253

1 reference

Effect of screening and adjuvant therapy on mortality from breast cancer

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Exemestane: a review of its clinical efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

The pharmacology of letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Early discontinuation of tamoxifen: a lesson for oncologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

First--select the target: better choice of adjuvant treatments for breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Breast cancer: bisphosphonate therapy for metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Overcoming endocrine therapy resistance by signal transduction inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Steroid sulfatase: a new target for the endocrine therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.9.1243

10.1586/14737140.7.9.1243

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference